agilon health (NYSE:AGL) Downgraded by Deutsche Bank Aktiengesellschaft

agilon health (NYSE:AGL) was downgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a report issued on Tuesday, Briefing.com reports. They presently have a $12.00 price objective on the stock, down from their prior price objective of $27.00. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential upside of 4.21% from the company’s current price.

Several other equities analysts have also recently weighed in on AGL. The Goldman Sachs Group cut their price objective on agilon health from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, November 9th. Benchmark reduced their price objective on agilon health from $28.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, November 15th. Royal Bank of Canada lowered their price objective on shares of agilon health from $28.00 to $23.00 and set an “outperform” rating on the stock in a research note on Friday, November 3rd. TD Cowen cut their target price on shares of agilon health from $29.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. Finally, Truist Financial decreased their price target on shares of agilon health from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.50.

agilon health Stock Performance

Shares of AGL opened at $11.52 on Tuesday. The company has a market capitalization of $4.68 billion, a PE ratio of -52.34 and a beta of 0.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.50 and a quick ratio of 1.50. agilon health has a one year low of $10.80 and a one year high of $29.44. The company’s fifty day moving average price is $16.90 and its 200 day moving average price is $18.31.

Insider Activity

In other news, CAO Timothy Gertsch sold 26,250 shares of agilon health stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $18.61, for a total transaction of $488,512.50. Following the sale, the chief accounting officer now directly owns 17,121 shares in the company, valued at approximately $318,621.81. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CAO Timothy Gertsch sold 26,250 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.61, for a total value of $488,512.50. Following the completion of the transaction, the chief accounting officer now directly owns 17,121 shares of the company’s stock, valued at approximately $318,621.81. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Benjamin Shaker sold 18,750 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $18.05, for a total value of $338,437.50. Following the completion of the sale, the insider now directly owns 79,543 shares in the company, valued at approximately $1,435,751.15. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On agilon health

Large investors have recently made changes to their positions in the company. FMR LLC grew its stake in agilon health by 17.1% during the first quarter. FMR LLC now owns 54,656,726 shares of the company’s stock worth $1,298,097,000 after buying an additional 7,985,420 shares during the last quarter. Capital World Investors increased its holdings in agilon health by 21.0% during the 2nd quarter. Capital World Investors now owns 51,347,600 shares of the company’s stock valued at $890,367,000 after purchasing an additional 8,911,629 shares in the last quarter. Morgan Stanley raised its position in agilon health by 8.9% in the 3rd quarter. Morgan Stanley now owns 44,819,378 shares of the company’s stock valued at $795,992,000 after purchasing an additional 3,674,311 shares during the last quarter. Vanguard Group Inc. boosted its stake in agilon health by 14.7% in the third quarter. Vanguard Group Inc. now owns 18,770,560 shares of the company’s stock worth $439,605,000 after purchasing an additional 2,407,116 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of agilon health by 11.0% during the first quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company’s stock worth $470,953,000 after purchasing an additional 1,834,890 shares during the last quarter.

agilon health Company Profile

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2022, it served approximately 269,500 medicare advantage members and 89,000 Medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.